Market Cap : 1.77 B | Enterprise Value : 1.78 B | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Myovant Sciences's earnings per share without non-recurring items for the three months ended in Jun. 2022 was $-0.22. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.76.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Myovant Sciences's EPS without NRI or its related term are showing as below:
MYOV's 3-Year EPS without NRI Growth Rate is ranked better thanMyovant Sciences's EPS (Diluted) for the three months ended in Jun. 2022 was $-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.76.
Myovant Sciences's EPS (Basic) for the three months ended in Jun. 2022 was $-0.22. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $-1.76.
The historical data trend for Myovant Sciences's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Myovant Sciences's EPS without NRI, along with its competitors' market caps and EPS without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's EPS without NRI distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's EPS without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Non Operating Income refers to an entry that appears on a company's financial statements that is unlikely to happen again. It represents a one-time expense involving an unpredictable event and is not part of a firm's normal, day-to-day operations.
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Myovant Sciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Valente Nancy | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Mehra Uneek | officer: Principal Financial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Merendino Lauren | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Marek David C | director, officer: Principal Executive Officer | C/O WEBMD HEALTH CORP. 111 EIGHTH AVENUE NEW YORK NY 10011 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME CHUO-KU TOKYO M0 103-6020 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Lo Andrew | 10 percent owner | C/O ALPHASIMPLEX GROUP, LLC ONE CAMBRIDGE CENTER, 9TH FLOOR CAMBRIDGE MA 02142 |
Viking Global Equities Master Ltd. | 10 percent owner | 55 RAILROAD AVENUE GREENWICH CT 06830 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
From GuruFocus
Other Sources
By Zacks 2021-10-26
By Zacks 2020-12-29
By Zacks 2021-04-13
By Seekingalpha 2021-01-19
By Seekingalpha 2022-01-26
By Zacks 2021-07-28
By Zacks 2021-10-29
By Zacks 2021-02-11
By Seekingalpha 2021-05-24
By Zacks 2021-03-25
By Zacks 2020-12-29
By Zacks 2021-09-10
By Zacks 2020-12-16
By Seekingalpha 2021-06-02